Endo Pharmaceuticals Holdings (ENDP) Reports In-Line Q1 EPS; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts ENDP Hot Sheet
Price: $0.29 --0%
Financial Fact:
Research and development: 28.73M
Today's EPS Names:
SFST, VLTO, CLIR, More
Financial Fact:
Research and development: 28.73M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q1 EPS of $0.87, in-line with the analyst estimate of $0.87. Revenue for the quarter came in at $691 million versus the consensus estimate of $700.34 million.
Endo Pharmaceuticals Holdings reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Endo Pharmaceuticals Holdings reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novartis hikes full-year guidance as Q1 results exceed estimates, shares pop
- Globe Life Inc. (GL) Misses Q1 EPS by 1c, Offers Guidance
- Nucor (NUE) Misses Q1 EPS by 21c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
